Zi-Chen Yu, Zheng-Kang Fang, Yang Yu, Si-Yu Liu, Kai-Di Wang, Zhe-Jin Shi, Li-Ming Jin, Xiao-Kun Huang, Yi Lu, Guo-Liang Shen, Jun-Wei Liu, Dong-Sheng Huang, Cheng-Wu Zhang, Lei Liang
{"title":"双表型肝细胞癌根治性肝切除术后的临床特征、复发模式和长期生存结局。","authors":"Zi-Chen Yu, Zheng-Kang Fang, Yang Yu, Si-Yu Liu, Kai-Di Wang, Zhe-Jin Shi, Li-Ming Jin, Xiao-Kun Huang, Yi Lu, Guo-Liang Shen, Jun-Wei Liu, Dong-Sheng Huang, Cheng-Wu Zhang, Lei Liang","doi":"10.2147/JHC.S493094","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aims: </strong>Dual-phenotype hepatocellular carcinoma (DPHCC) is discernible from classical HCC (CHCC) in its morphology and is characterized by the co-expression of both CHCC and cholangiocyte markers. This study aimed to clarify the difference between DPHCC and CHCC after surgery.</p><p><strong>Methods: </strong>Patients with HCC after surgery were collected. The clinical characteristics, patterns of recurrence, and survival outcomes of patients with DPHCC and CHCC were compared. Multivariate analyses were used to determine the independent risk factors that influence the prognosis of patients.</p><p><strong>Results: </strong>Patients with DPHCC (n = 141) account for 26% of the total patients (n = 541). Compared to patients with CHCC, patients with DPHCC are significantly associated with incomplete capsules, microvascular invasion, and poor differentiation (all P < 0.05). Compared to patients with CHCC, the 5-year overall survival (OS) (56% vs 43%) and recurrence-free survival (RFS) (35% vs 28%) are lower in patients with DPHCC. Meanwhile, among patients with tumor recurrence after surgery, patients with DPHCC have a higher proportion of advanced-stage tumors, and extrahepatic metastasis (all P < 0.05). Moreover, multivariate analysis showed that DPHCC is an independent risk factor for both OS (HR 1.399, 95% CI 1.061-1.845, P = 0.017) and RFS (HR 1.313, 95% CI 1.033-1.669, P = 0.026).</p><p><strong>Conclusion: </strong>DPHCC, an aggressive HCC subtype with poor differentiation and high invasiveness, shows inferior RFS and OS post-liver resection compared to CHCC. Clinicians' recognition and addressing of its unique challenges can improve DPHCC patients' prognosis and QoL.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"183-192"},"PeriodicalIF":4.2000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789503/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Clinical Characteristics, Patterns of Recurrence, and Long-Term Survival Outcomes of Dual-Phenotype Hepatocellular Carcinoma After Curative Liver Resection.\",\"authors\":\"Zi-Chen Yu, Zheng-Kang Fang, Yang Yu, Si-Yu Liu, Kai-Di Wang, Zhe-Jin Shi, Li-Ming Jin, Xiao-Kun Huang, Yi Lu, Guo-Liang Shen, Jun-Wei Liu, Dong-Sheng Huang, Cheng-Wu Zhang, Lei Liang\",\"doi\":\"10.2147/JHC.S493094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background & aims: </strong>Dual-phenotype hepatocellular carcinoma (DPHCC) is discernible from classical HCC (CHCC) in its morphology and is characterized by the co-expression of both CHCC and cholangiocyte markers. This study aimed to clarify the difference between DPHCC and CHCC after surgery.</p><p><strong>Methods: </strong>Patients with HCC after surgery were collected. The clinical characteristics, patterns of recurrence, and survival outcomes of patients with DPHCC and CHCC were compared. Multivariate analyses were used to determine the independent risk factors that influence the prognosis of patients.</p><p><strong>Results: </strong>Patients with DPHCC (n = 141) account for 26% of the total patients (n = 541). Compared to patients with CHCC, patients with DPHCC are significantly associated with incomplete capsules, microvascular invasion, and poor differentiation (all P < 0.05). Compared to patients with CHCC, the 5-year overall survival (OS) (56% vs 43%) and recurrence-free survival (RFS) (35% vs 28%) are lower in patients with DPHCC. Meanwhile, among patients with tumor recurrence after surgery, patients with DPHCC have a higher proportion of advanced-stage tumors, and extrahepatic metastasis (all P < 0.05). Moreover, multivariate analysis showed that DPHCC is an independent risk factor for both OS (HR 1.399, 95% CI 1.061-1.845, P = 0.017) and RFS (HR 1.313, 95% CI 1.033-1.669, P = 0.026).</p><p><strong>Conclusion: </strong>DPHCC, an aggressive HCC subtype with poor differentiation and high invasiveness, shows inferior RFS and OS post-liver resection compared to CHCC. Clinicians' recognition and addressing of its unique challenges can improve DPHCC patients' prognosis and QoL.</p>\",\"PeriodicalId\":15906,\"journal\":{\"name\":\"Journal of Hepatocellular Carcinoma\",\"volume\":\"12 \",\"pages\":\"183-192\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-01-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789503/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatocellular Carcinoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/JHC.S493094\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S493094","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景与目的:双表型肝细胞癌(DPHCC)在形态学上与经典HCC (CHCC)不同,其特征是CHCC和胆管细胞标志物共同表达。本研究旨在阐明术后DPHCC与CHCC的区别。方法:收集肝细胞癌术后患者。比较DPHCC和CHCC患者的临床特征、复发模式和生存结局。采用多因素分析确定影响患者预后的独立危险因素。结果:DPHCC患者141例,占541例患者的26%。与CHCC患者相比,DPHCC患者囊膜不全、微血管侵犯、分化差显著相关(均P < 0.05)。与CHCC患者相比,DPHCC患者的5年总生存率(OS)(56%对43%)和无复发生存率(RFS)(35%对28%)较低。同时,在术后肿瘤复发患者中,DPHCC患者出现晚期肿瘤及肝外转移的比例较高(均P < 0.05)。此外,多因素分析显示,DPHCC是OS (HR 1.399, 95% CI 1.061 ~ 1.845, P = 0.017)和RFS (HR 1.313, 95% CI 1.033 ~ 1.669, P = 0.026)的独立危险因素。结论:DPHCC是一种分化差、侵袭性强的侵袭性肝癌亚型,肝切除术后的RFS和OS均低于CHCC。临床医生对其独特挑战的认识和解决可以改善DPHCC患者的预后和生活质量。
The Clinical Characteristics, Patterns of Recurrence, and Long-Term Survival Outcomes of Dual-Phenotype Hepatocellular Carcinoma After Curative Liver Resection.
Background & aims: Dual-phenotype hepatocellular carcinoma (DPHCC) is discernible from classical HCC (CHCC) in its morphology and is characterized by the co-expression of both CHCC and cholangiocyte markers. This study aimed to clarify the difference between DPHCC and CHCC after surgery.
Methods: Patients with HCC after surgery were collected. The clinical characteristics, patterns of recurrence, and survival outcomes of patients with DPHCC and CHCC were compared. Multivariate analyses were used to determine the independent risk factors that influence the prognosis of patients.
Results: Patients with DPHCC (n = 141) account for 26% of the total patients (n = 541). Compared to patients with CHCC, patients with DPHCC are significantly associated with incomplete capsules, microvascular invasion, and poor differentiation (all P < 0.05). Compared to patients with CHCC, the 5-year overall survival (OS) (56% vs 43%) and recurrence-free survival (RFS) (35% vs 28%) are lower in patients with DPHCC. Meanwhile, among patients with tumor recurrence after surgery, patients with DPHCC have a higher proportion of advanced-stage tumors, and extrahepatic metastasis (all P < 0.05). Moreover, multivariate analysis showed that DPHCC is an independent risk factor for both OS (HR 1.399, 95% CI 1.061-1.845, P = 0.017) and RFS (HR 1.313, 95% CI 1.033-1.669, P = 0.026).
Conclusion: DPHCC, an aggressive HCC subtype with poor differentiation and high invasiveness, shows inferior RFS and OS post-liver resection compared to CHCC. Clinicians' recognition and addressing of its unique challenges can improve DPHCC patients' prognosis and QoL.